SILVER SPRING, USA (Reuters) – A panel of advisers said

that heart for new studies should require

drugs against obesity, possibly adding a new

obstacle in the way of its adoption.

The food and drug administration panel of

United States ( FDA) voted 17 to 6 that regulators should

forcing companies to conduct studies of heart impact

to sell their drugs in United States, even if the

clinical trials do not show initially evidence of risk

heart.

However, the panel did not discuss even if the evidence

should be out before or after approval.

The news could affect Arena Pharmaceuticals Vivus Inc.

Inc and Orexigen Therapeutics Inc, which are competing for

bring the first drug against obesity to market more of

a decade.